1
|
Lechat P. Potentiel Impact thérapeutique de la substitution en cours de traitement d’un princeps par un générique : limites de la bioéquivalence moyenne pour les médicaments à marge thérapeutique étroite. BULLETIN DE L'ACADÉMIE NATIONALE DE MÉDECINE 2023. [DOI: 10.1016/j.banm.2022.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/05/2023]
|
2
|
Lechat P. Inefficacité et dangerosité potentielle de l’hydroxychloroquine pour traiter une infection par le coronavirus Sars-Cov2. ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX - PRATIQUE 2020; 2020:25-27. [PMID: 32837201 PMCID: PMC7386302 DOI: 10.1016/j.amcp.2020.07.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
3
|
Sallah K, Gault N, Van Gysel D, Luquiens G, Lechat P. Élaboration d’un référentiel mettant en lien des champs textuels d’indications thérapeutiques avec des libellés diagnostiques, en vue de la détection de prescriptions hors AMM dans les dossiers médicaux. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Nataf P, Guettier C, Hadjiisky P, Lechat P, Regan M, Gouezo R, Gerota J, Pavie A, Cabrol C, Gandjbakhch I. Evaluation of Cryopreserved Arteries as Alternative Small Vessel Prostheses. Int J Artif Organs 2018. [DOI: 10.1177/039139889501800404] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Biologic or synthetic grafts have had limited success in small vessel applications. Studies were initiated to assess the potential use of cryopreserved (CP) arteries as coronary artery bypass conduits. Sheep carotid arteries (internal diameter: 4 mm; length: 10 cm) were cryopreserved in a nutrient media containing 10% DMSO and were stored in a nitrogen vapor at -150°C. After thawing, histological, enzyme-histochemical and functional studies showed slight histological alterations, preservation of enzymal activities and an abolition of the contractile response. In a sheep model, arterial substitution of a 10 cm segment of carotid artery was realised by implantation of fresh autografts (n=4); fresh allografts (n=9) and CP allografts (n=9). After 3 months, all autografts were patent with slight histological alterations. Fresh and CP allografts showed similar modifications: patency rate was 7/9 in both groups. Intimal thickening with cell proliferation was seen in fresh (3/7) and CP (4/8) arteries; loss of smooth muscle medial cells was constant. Adventitia was always involved by a marked inflammatory reaction. One characteristic of CP allografts was the frequent presence of large dystrophic calcifications. In conclusion, morphologic and functional arterial changes occurred after freezing and thawing. In spite of vascular rejection, the patency rate of allografts after 3 months of implantation in arterial circulation remained high and does not seem influenced by cryopreservation.
Collapse
|
5
|
Janus N, Cavagna F, Beauvais F, Garenaux M, Livet D, Bergmann J, Pol S, Sicard J, Monchecourt F, Hanon O, Lechat P, Deray G. Adaptation posologique et fonction rénale chez la personne âgée en officine. Résultat de l’étude IPOP. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Bocquet F, Fusier I, Cordonnier A, Lechat P, Paubel P. Budget Impact Analysis of Implementing Tenders Between The Branded Infliximab And Its Biosimilars In The Public Hospitals of Paris. VALUE IN HEALTH 2015. [PMID: 0 DOI: 10.1016/j.jval.2015.09.2275] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
|
7
|
Lechat P, Eugène M, Komajda M. Mécanismes de la contractilité cardiaque. Med Sci (Paris) 2013. [DOI: 10.4267/10608/3441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
|
9
|
Costedoat-Chalumeau N, Galicier L, Francès C, Aumaitre O, Lioté F, Le Guern V, Limal N, Smail A, Ninet J, Perard L, Le Huong Thi D, Asli B, Grandpeix C, Sailler L, Ackermann F, Papo T, Brihaye B, Fain O, Stirnemann J, Jallouli M, Leroux G, Hulot JS, Lechat P, Musset L, Piette JC, Amoura Z. Étude des facteurs associés à une concentration basse d’hydroxychloroquine chez 523 patients inclus dans l’étude Plaquénil Lupus Systémique (PLUS, étude française multicentrique). Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Costedoat-Chalumeaum N, Galicier L, Aumaitre O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Grandpeix C, Pourrat J, Ackermann F, Papo T, Brihaye B, Fain O, Stirnemann J, Cohen J, Jallouli M, Hulot JS, Lechat P, Musset L, Piette JC, Amoura Z. Données épidémiologiques d’une cohorte française multicentrique de 569 patients lupiques. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
11
|
Costedoat-Chalumeau N, Jallouli M, Galicier L, Aumaître O, Francès C, Le Guern V, Liote F, Smail A, Limal N, Pérard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Grandpeix C, Pourrat J, Ackermann F, Papo T, Brihaye B, Fain O, Stirnemann J, Cohen J, Tanguy ML, Hulot JS, Lechat P, Musset L, Piette JC, Amoura Z. Description des patients lupiques inclus dans l’étude PLUS (Plaquénil Lupus Systémique, étude française multicentrique) en fonction de leur origine ethnique. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy ML, Lechat P. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009; 30:2186-92. [DOI: 10.1093/eurheartj/ehp323] [Citation(s) in RCA: 109] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Streichenberger G, Lechat P. Application du réendormissement provoqué chez le rat par variation brusque de la température ambiante à l’étude de l’antagonisme entre neurostimulants et hypnotiques. Pharmacology 2008. [DOI: 10.1159/000137078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
14
|
Lechat P, Streichenberger G, Maget E. Etude pharmacologique du réendormissement provoqué chez le rat par variation brusque de température ambiante. Pharmacology 2008. [DOI: 10.1159/000135731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
15
|
Lechat P, Griffié R, Deleau D. Du renouvellement immédiat de l’anesthésie locale. Pharmacology 2008. [DOI: 10.1159/000135252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
16
|
Lechat P, Deleau D, Griffié R. Influence de l’ion potassium sur l’activité des anesthésiques locaux. Pharmacology 2008. [DOI: 10.1159/000135474] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
17
|
Lebaudy C, Hulot JS, Amoura Z, Costedoat-Chalumeau N, Serreau R, Ankri A, Conard J, Cornet A, Dommergues M, Piette JC, Lechat P. Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy. Clin Pharmacol Ther 2008; 84:370-7. [DOI: 10.1038/clpt.2008.73] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
18
|
Leroux G, Costedoat-Chalumeau N, Hulot JS, Amoura Z, Frances C, Aymard G, Lechat P, Piette JC. Relation entre le tabagisme actif et les concentrations sanguines d'hydroxychloroquine et de déséthylchloroquine chez 223 patients. Rev Med Interne 2007. [DOI: 10.1016/j.revmed.2007.03.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Costedoat-Chalumeau N, Leroux G, Sellam J, Amoura Z, Hulot JS, Aymard G, Lechat P, Mariette X, Piette JC. Étude de la pharmacocinétique de l'hydroxychloroquine chez cinq patients traités par une posologie alternée de 1 ou deux comprimés par jour. Rev Med Interne 2007. [DOI: 10.1016/j.revmed.2007.03.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Cohen Aubart F, Hansel B, Hulot JS, Lechat P, Bruckert E. [New insights and perspectives in the management of dyslipidemia]. Rev Med Interne 2007; 28:537-44. [PMID: 17337099 DOI: 10.1016/j.revmed.2007.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2006] [Accepted: 01/27/2007] [Indexed: 11/21/2022]
Abstract
PURPOSE Recent end point trials of lipid-lowering drugs have shown that patients at very high-risk for coronary disease benefit from treatments that lowers low density lipoprotein cholesterol (LDL cholesterol) plasma levels< or =70 mg/dl and that patients with at least 2 risk factors benefit from LDL cholesterol levels< or =100 mg/dl. Epidemiologic studies have shown that the concentration of high density lipoprotein cholesterol (HDL cholesterol) is a strong, independent, inverse predictor of coronary disease risk. Innovative pharmacological approaches to raise low HDL cholesterol levels are currently of considerable interest, especially for patients with type 2 diabetes or metabolic syndrome. RESULTS Rosuvastatin has shown superior efficacy in lowering LDL cholesterol, although evidence of clinical benefit is actually lacking. Ezetimibe is a lipid-lowering drug that inhibits absorption of dietary and biliary cholesterol. Its co-administration with statin has given very interesting results. Niacin is the most effective of currently available options for raising HDL cholesterol, although tolerability can be an issue, with serious side effects such as loss of glucose control and liver toxicity. Flushing may occur in 80% of treated patients. Two CETP inhibitors have shown therapeutical efficacy to raise HDL cholesterol, but clinical benefit remains uncertain.
Collapse
|
21
|
Costedoat-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, Piette JC. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 2007; 46:808-10. [PMID: 17202178 DOI: 10.1093/rheumatology/kel402] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE The antimalarial agents chloroquine (CQ) and hydroxychloroquine (HCQ) are used in long-term treatment of connective tissue diseases (CTDs). A high incidence of heart conduction disorders, including bundle-branch block and incomplete or complete atrioventricular block, has been observed among patients treated with CQ. Since no data were available for HCQ, we studied electrocardiograms (ECGs) in 85 unselected patients with CTD treated with HCQ as the sole antimalarial. METHODS Eighty-five unselected out-patients treated with HCQ for a minimum of 1 yr, and without established cardiac diseases had standard 12-lead ECGs. RESULTS Two incomplete right bundle-branch blocks and one left bundle-branch block were observed. No atrioventricular block was observed. The mean PR interval was 137 +/- 20 ms (range 99-188). The mean QTc interval was 410 ms (range 349-464). The mean heart rate was 73 beats/min (range 53-102). CONCLUSION PR interval, QTc interval and heart rate were not different from normal values. The rate of heart conduction disorders was similar to what is expected in the general population, and contrasted with prior results in CQ-treated patients. Our results add further evidence on the safety of HCQ compared with CQ.
Collapse
|
22
|
Massol J, Zylberman M, Goehrs JM, Abenhaïm L, Ambrosi P, Bardou M, Boissel JP, Brun C, Castaigne A, Chassany O, de Bels F, de Sahb-Berkovitch R, El-Hasnaoui A, Fagagni F, Fourrier-Reglat A, Gastaldi-Meninger C, Goehrs JM, Gueffier F, Hotton JM, Ichou F, Lechat P, Maillère P, Meyer F, Micallef J, Molimard M, Moreau-Defarges T, Perillat A, Pigeon M, Poitrinal P, Rey-Quino C, Ricordeau P, Ropers J. Utilisation des études étrangères : transposition des résultats, prédiction des effets thérapeutiques en population française, modélisation de l’Intérêt de Santé Publique. Therapie 2006; 61:481-9. [DOI: 10.2515/therapie:2007002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
23
|
Lechat P, Priollet P. Quel effet bénéfique attendude l’aspirine dans l’artériopathieoblitérante des membresinférieurs? Presse Med 2006. [DOI: 10.1016/s0755-4982(06)74898-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
24
|
Costedoat-Chalumeau N, Amoura Z, Hulot JS, Lechat P, Piette JC. Faut-il doser l'hydroxychloroquine chez les patients lupiques ? Rev Med Interne 2006; 27:655-7. [PMID: 16766090 DOI: 10.1016/j.revmed.2006.05.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2006] [Accepted: 05/11/2006] [Indexed: 10/24/2022]
|
25
|
Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318-24. [PMID: 16871247 DOI: 10.1038/sj.ki.5001657] [Citation(s) in RCA: 224] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Cardiovascular events (CVEs) are the leading cause of death in chronic hemodialysis patients. Results of trials in non-end-stage renal disease (ESRD) patients cannot be extrapolated to patients with ESRD. It is critical to test cardiovascular therapies in these high-risk patients who are usually excluded from major cardiovascular trials. The study objective was to evaluate the effect of fosinopril on CVEs in patients with ESRD. Eligible patients were randomized to fosinopril 5 mg titrated to 20 mg daily (n=196) or placebo (n=201) plus conventional therapy for 24 months. The primary end point was combined fatal and nonfatal first major CVEs (cardiovascular death, resuscitated death, nonfatal stroke, heart failure, myocardial infarction, or revascularization). No significant benefit for fosinopril was observed in the intent to treat analysis (n=397) after adjusting for independent predictors of CVEs (RR=0.93, 95% confidence interval (CI) 0.68-1.26, P=0.35). The per protocol secondary supportive analysis (n=380) found a trend towards benefit for fosinopril (adjusted RR=0.79 (95% CI 0.59-1.1, P=0.099)). In the patients who were hypertensive at baseline, systolic and diastolic blood pressures were significantly decreased in the fosinopril as compared to the placebo group. After adjustment for risk factors, trends were observed suggesting fosinopril may be associated with a lower risk of CVEs. These trends may have become statistically significant had the sample size been larger, and these findings warrant further study.
Collapse
|